الفهرس | Only 14 pages are availabe for public view |
Abstract Background: chronic myeloid leukemia (CML) is characterized by abnormal molecular mutations, abnormal expression of the BCR/ABL1 oncogene. The BCR/ABL1 tyrosine kinase inhibitors (TKIs) are considered a gold standard of treatment of patients with newly diagnosed CML Multiple vascular venous events are reported in patients with CML treated with TKIs so vascular safety is an emerging issue. Whereas imatinib exhibits a well-documented and favorable long-term safety profile without obvious accumulation of vascular events., several types of vascular adverse events (VAEs). Aim: To estimate the incidence of venous insults by venous Color Doppler in patients with CML treated with different tyrosine kinase inhibitors. Patients and Methods: we conducted a case control study including 70 CML patients and 50 healthy controls, cases were sub grouped into three groups’ imatinib 400, nilotinib 800 mg and nilotinib 600 mg. all patients were assessed for venous insults using color vascular doppler and its correlation with different TKIs. Results: Our results showed BCR ABL level was significantly the highest level in imatinib 400 mg group and the lowest level in nilotinib 600 mg group with p value 0.022, post-hoc study for the comparison of BCR ABL and the difference was between imatinib and nilotinib revealed statistical difference between imatinib and both concentrations of nilotinib in initial BCR ABL which may reflect later results of why BCR ABL in remission was in favor for nilotinib to imatinib. Our data showed the highest incidence of remission was reported in nilotinib group (62.7%), mean Hb concentration was lower in patients with remission compared to non-remission BCR ABL, while mean platelet count was higher among remission arms. Conclusion: We finally concluded that there is no statistically significant difference in the incidence of venous insults among patients diagnosed with chronic myeloid leukemia treated with imatinib or nilotinib and healthy controls |